Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/III study of IBI188 plus azacitidine in newly diagnosed intermediate- or high-risk myelodysplastic syndrome
CTR20201039Phase 3Suspended
- Sponsor
- InnoCare Pharma
- Start
- Sep 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of letaplimab, azacitidine in myelodysplastic syndrome (MDS), sponsored by InnoCare Pharma. Started Sep 2020; status: suspended.
02
Drugs
letaplimabazacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on CTR20201039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201039.